Lumos Diagnostics Holdings Ltd. (AU:LDX) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Lumos Diagnostics has secured a $41.38/test reimbursement rate for its FebriDx diagnostic test from the Centers for Medicare and Medicaid Services, effective January 2025. The approval is expected to enhance accessibility and adoption of FebriDx, which helps differentiate between bacterial and viral infections, addressing antibiotic resistance concerns. This milestone is seen as a significant step in the U.S. commercialization strategy for Lumos’ innovative diagnostic solutions.
For further insights into AU:LDX stock, check out TipRanks’ Stock Analysis page.